Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q1 2026 · 10-Q
Revenue$152.46K$152.46K+499.6% vs Q1 2025 Net Income-$3.00M-$3.00MN/M vs Q1 2025 EPS Diluted-$0.21-$0.21N/M vs Q1 2025 Operating Income-$2,998,898N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,520,644N/M Margins · derivedOperating margin-1967.1%+16049.7 pt vs Q1 2025
Net margin-1967.7%+15251.4 pt vs Q1 2025
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end